Table Of Contents

1. Introduction
1.1. Objectives Of The Study
1.2. Market Definition
1.3. Overview Of North America Cancer Diagnostics Market
1.4. Currency And Pricing
1.5. Limitation
1.6. Markets Covered
2. Market Segmentation
2.1. Markets Covered
2.2. Geographic Scope
2.3. Years Considered For The Study
2.4. Currency And Pricing
2.5. Research Methodology
2.6. Primary Interviews With Key Opinion Leaders
2.7. Secondary Sources
2.8. Assumptions
3. Market Overview
3.1. Drivers
3.1.1. Growth Of Aging Population And Rising Prevalence Of Cancer
3.1.2. Government Initiatives For Funding And Awareness About Cancer
3.1.3. Key Players Focusing On Strategic Decisions To Gain Market Share
3.1.4. Increasing Prevelance Of Cancer
?
3.2. Restraints
3.2.1. Stringent Reulations Imposed By International And Local Authorities
3.2.2. Shortage Of Skilled And Trained Professionals
3.3. Opportunities
3.3.1. Nanotechnology; Forthcoming Revolution In Cancer Diagnosis
3.3.2. Artificial Intelligence And The Imminent Health Revolution
3.3.3. Growing Medical Tourism In Asia
3.4. Challenges
3.4.1. Increasing Rivalry Among The Competitors
3.4.2. Poor Access To Cancer Detection And High Treatment Cocts In Lower Income Countries
4. Premium Insights
5. Executive Summary
6. North America Cancer Diagnostics Market, By Technology
6.1. Overview
6.2. Platform Based
6.2.1. Polymerase Chain Reaction(Pcr)
6.2.2. In Situ Hybridization (Ish)
6.2.3. Immunohistochemistry(Ihc)
6.2.4. Next Generation Sequencing (Ngs)
6.2.5. Dna Microarrays
6.2.6. Flow Cytometry
6.3. Instrument Based
6.3.1. Imaging
6.3.1.1. Magentic Resonance Imaging (Mri)
6.3.1.2. Ct(Computed Tomography)
6.3.1.3. Positron Emission Tomography- Computed Tomography (Pet-Ct)
6.3.1.4. Mammography
6.3.1.5. Ultrasound
6.3.2. Biopsy
7. North America Cancer Diagnostics Market, By Application
7.1. Overview
7.2. Lung Cancer
7.3. Breast Cancer
7.4. Colorectal Cancer
7.5. Melanoma
7.6. Others
8. North America Cancer Diagnostics Market, By Geography
8.1. Overview
8.2. North America Cancer Diagnostics Market
8.2.1. U.S.Cancer Diagnostics Market
8.2.2. Canada Cancer Diagnostics Market
8.2.3. Mexico Cancer Diagnostics Market
9. North America Cancer Diagnostics Market, Company Landscape
9.1. Company Share Analysis; North America Cancer Diagnostics Imaging Market
9.2. Company Share Analysis; North America Cancer Diagnostics Platform Based Market
10. Company Profiles
10.1. C. R. Bard, Inc.
10.1.1. Company Overview
10.1.2. Revenue Analysis
10.1.3. Product Portfolio
10.1.4. Recent Developments
10.2. Illumina, Inc.
10.2.1. Company Overview
10.2.2. Revenue Analysis
10.2.3. Recent Developments
10.2.4. Product Portfolio
10.3. Qiagen
10.3.1. Company Overview
10.3.2. Revenue Analysis
10.3.3. Recent Developments
10.3.4. Product Portfolio
10.4. Abbott
10.4.1. Company Overview
10.4.2. Revenue Analysis
10.4.3. Recent Developments
10.4.4. Product Portfolio
10.5. Siemens Healthcare Gmbh
10.5.1. Company Overview
10.5.2. Revenue Analysis
10.5.3. Recent Developments
10.5.4. Product Portfolio
10.6. Agilent Technologies
10.6.1. Company Overview
10.6.2. Revenue Analysis
10.6.3. Product Portfolio
10.6.4. Recent Developments
10.7. Thermo Fisher Scientific Inc.
10.7.1. Company Overview
10.7.2. Revenue Analysis
10.7.3. Product Portfolio
10.7.4. Recent Developments
10.8. Becton, Dickinson And Company
10.8.1. Company Overview
10.8.2. Revenue Analysis
10.8.3. Product Portfolio
10.8.4. Recent Developments
10.9. Ge Healthcare
10.9.1. Company Overview
10.9.2. Revenue Analysis
10.9.3. Product Portfolio
10.9.4. Recent Developments
10.10. F. Hoffmann-La Roche Ltd
10.10.1. Company Overview
10.10.2. Revenue Analysis
10.10.3. Product Portfolio
10.10.4. Recent Developments
10.11. Hologic Inc.
10.11.1. Company Overview
10.11.2. Revenue Analysis
10.11.3. Recent Developments
10.11.4. Product Portfolio
10.12. Koninklijhe Philips N.V.
10.12.1. Company Overview
10.12.2. Revenue Analysis
10.12.3. Product Portfolio
10.12.4. Recent Developments
11. Related Reports